Radioactive drug tested to stop Cancer's return after liver surgery
NCT ID NCT05987176
Summary
This study tested whether giving Lutathera, a targeted radioactive drug, after surgery to remove neuroendocrine tumor spread in the liver could prevent the cancer from coming back. It compared this treatment against standard monitoring and supportive care in patients whose primary stomach, pancreas, or gut tumors were also removed. The main goal was to see if patients receiving Lutathera remained cancer-free longer over three years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
Conditions
Explore the condition pages connected to this study.